Valuation: Bicycle Therapeutics plc

Market Cap 29Cr 26Cr 24Cr 22Cr 41Cr 2.8TCr 42Cr 281.68Cr 110.05Cr 1.37TCr 109.02Cr 106.67Cr 4.75TCr P/E 2026 *
-1.74x
P/E 2027 * -1.91x
Enterprise Value -22Cr -19Cr -18Cr -17Cr -31Cr -2.13TCr -32Cr -214.91Cr -84Cr -1.05TCr -83Cr -81Cr -3.63TCr EV / Sales 2026 *
-13x
EV / Sales 2027 * -7.33x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day-6.37%
1 week-7.24%
Current month-7.90%
1 month-1.39%
3 months-19.32%
6 months-44.21%
Current year-44.84%
1 week 3.9
Extreme 3.9013
4.34
1 month 3.9
Extreme 3.9013
4.52
Current year 3.9
Extreme 3.9013
7.34
1 year 3.9
Extreme 3.9013
9.16
3 years 3.9
Extreme 3.9013
28.67
5 years 3.9
Extreme 3.9013
62.08
10 years 3.9
Extreme 3.9013
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Free

Chief Technology Officer

60,000 0.1580%
15/07/26 Free

Chief Financial Officer

60,000 0.1580%
15/07/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-7.24%-54.59%-84.88% 29Cr
-1.92%-1.57%+48.70%+84.37% 5.59TCr
+0.93%+6.97%+62.83%+67.97% 5.67TCr
-2.85%-2.31%-22.00%-16.50% 2.33TCr
-0.40%-1.06%+3.53%+423.80% 2.33TCr
-0.36%-0.56%+36.00%-3.93% 2.05TCr
-1.34%+0.51%+25.02%-30.27% 1.78TCr
-1.44%-1.63%+37.07%+589.93% 1.59TCr
-1.30%-9.92%+160.67%+284.37% 1.46TCr
-0.31%-0.76%+23.90%+179.01% 1.4TCr
Average -1.52%+0.38%+32.11%+149.39% 2.42TCr
Weighted average by Cap. -0.85%+1.47%+42.51%+138.08%

Financials

2026 *2027 *
Net sales 1.71Cr 1.5Cr 1.4Cr 1.28Cr 2.41Cr 164.52Cr 2.44Cr 17Cr 6.47Cr 81Cr 6.41Cr 6.28Cr 279.65Cr 1.55Cr 1.36Cr 1.27Cr 1.16Cr 2.19Cr 149.5Cr 2.22Cr 15Cr 5.88Cr 73Cr 5.83Cr 5.7Cr 254.12Cr
Net income -16Cr -14Cr -13Cr -12Cr -22Cr -1.53TCr -23Cr -153.87Cr -60Cr -751.09Cr -60Cr -58Cr -2.6TCr -16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -23Cr -158.58Cr -62Cr -774.1Cr -61Cr -60Cr -2.68TCr
Net Debt -51Cr -45Cr -42Cr -38Cr -72Cr -4.93TCr -73Cr -496.6Cr -194.01Cr -2.42TCr -192.2Cr -188.06Cr -8.38TCr -40Cr -35Cr -33Cr -30Cr -57Cr -3.89TCr -58Cr -392Cr -153.15Cr -1.91TCr -151.72Cr -148.45Cr -6.62TCr
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
25/26/25 $3.905 -6.13% 4,51,309
23/26/23 $4.160 -1.19% 1,54,162
22/26/22 $4.210 +1.20% 1,54,246
21/26/21 $4.160 0.00% 2,68,170
20/26/20 $4.160 -1.19% 3,07,617
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
4.160USD
Average target price
13.57USD
Spread / Average Target
+226.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock